CN1845999A - 在卵巢癌中作为预后和治疗靶标而被调控的基因 - Google Patents

在卵巢癌中作为预后和治疗靶标而被调控的基因 Download PDF

Info

Publication number
CN1845999A
CN1845999A CNA2004800250336A CN200480025033A CN1845999A CN 1845999 A CN1845999 A CN 1845999A CN A2004800250336 A CNA2004800250336 A CN A2004800250336A CN 200480025033 A CN200480025033 A CN 200480025033A CN 1845999 A CN1845999 A CN 1845999A
Authority
CN
China
Prior art keywords
gene
expression
ovarian cancer
sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800250336A
Other languages
English (en)
Chinese (zh)
Inventor
C·N·拉韦丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1845999A publication Critical patent/CN1845999A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2004800250336A 2003-07-02 2004-07-01 在卵巢癌中作为预后和治疗靶标而被调控的基因 Pending CN1845999A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48446503P 2003-07-02 2003-07-02
US60/484,465 2003-07-02

Publications (1)

Publication Number Publication Date
CN1845999A true CN1845999A (zh) 2006-10-11

Family

ID=34062046

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800250336A Pending CN1845999A (zh) 2003-07-02 2004-07-01 在卵巢癌中作为预后和治疗靶标而被调控的基因

Country Status (8)

Country Link
EP (1) EP1644522A2 (fr)
JP (1) JP2007526749A (fr)
CN (1) CN1845999A (fr)
AU (1) AU2004256182A1 (fr)
BR (1) BRPI0412110A (fr)
CA (1) CA2531091A1 (fr)
MX (1) MXPA05014220A (fr)
WO (1) WO2005005661A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106841622A (zh) * 2017-04-07 2017-06-13 南通大学附属医院 Scml2在诊断胃肠胰神经内分泌肿瘤中的应用
CN107385068A (zh) * 2010-08-27 2017-11-24 明斯特大学临床医学院 用于检测女性受试者患复发性流产、先兆子痫和/或胎儿生长受限的倾向的工具和方法
CN108085392A (zh) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 上皮性卵巢癌的生物标志物及其用途
CN110241198A (zh) * 2019-05-30 2019-09-17 成都吉诺迈尔生物科技有限公司 一种表征hHRD同源重组缺陷的基因组重组指纹及其鉴定方法
CN112229999A (zh) * 2020-09-01 2021-01-15 浙江省肿瘤医院 一种卵巢癌的预后诊断标志物Claudin21及其应用
CN113684277A (zh) * 2021-09-06 2021-11-23 南方医科大学南方医院 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100068207A1 (en) * 2005-04-07 2010-03-18 Abdallah Fanidi DDR2 in Cancer Diagnosis, Detection and Treatment
EP1806413A1 (fr) * 2006-01-06 2007-07-11 Oligene GmbH Procédé in vitro et outiles pour la détection des differents types de tumeur et prédiction des résultats d'intervention chirurgical du cancer de l'ovaire
PL2092081T3 (pl) * 2006-11-13 2013-07-31 Valipharma Sposoby i zastosowania obejmujące genetyczne nieprawidłowości w chromosomie 12
GB0815846D0 (en) * 2008-09-01 2008-10-08 Immunovia Ab diagnosis, prognosis and imaging of disease
MX341866B (es) 2010-01-11 2016-09-06 Genomic Health Inc Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
EP3004392B1 (fr) 2013-05-30 2020-09-30 Genomic Health, Inc. Algorithme de profil d'expression génique pour le calcul d'un score de récurrence pour un patient atteint d'un cancer rénal
CN103920150B (zh) * 2014-04-17 2016-02-03 北京大学第一医院 Satb1在治疗皮肤t细胞淋巴瘤中的应用
JP6436477B2 (ja) * 2014-05-13 2018-12-12 国立大学法人大阪大学 癌治療用医薬組成物
JP6168625B2 (ja) * 2016-01-12 2017-07-26 国立研究開発法人産業技術総合研究所 上皮性卵巣癌鑑別マーカー

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018542A2 (fr) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Compositions, trousses et methodes pour l'identification, l'analyse, la prevention et la therapie du cancer des ovaires
AU4592601A (en) * 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US20030003479A1 (en) * 2001-04-19 2003-01-02 Millennium Pharmaceutical, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2003021229A2 (fr) * 2001-09-05 2003-03-13 The Brigham And Women's Hospital, Inc. Tests diagnostiques et pronostiques

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107385068A (zh) * 2010-08-27 2017-11-24 明斯特大学临床医学院 用于检测女性受试者患复发性流产、先兆子痫和/或胎儿生长受限的倾向的工具和方法
CN106841622A (zh) * 2017-04-07 2017-06-13 南通大学附属医院 Scml2在诊断胃肠胰神经内分泌肿瘤中的应用
CN106841622B (zh) * 2017-04-07 2019-01-18 南通大学附属医院 Scml2在诊断胃肠胰神经内分泌肿瘤中的应用
CN108085392A (zh) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 上皮性卵巢癌的生物标志物及其用途
CN110241198A (zh) * 2019-05-30 2019-09-17 成都吉诺迈尔生物科技有限公司 一种表征hHRD同源重组缺陷的基因组重组指纹及其鉴定方法
CN112229999A (zh) * 2020-09-01 2021-01-15 浙江省肿瘤医院 一种卵巢癌的预后诊断标志物Claudin21及其应用
CN112229999B (zh) * 2020-09-01 2022-04-22 浙江省肿瘤医院 一种卵巢癌的预后诊断标志物Claudin21及其应用
CN113684277A (zh) * 2021-09-06 2021-11-23 南方医科大学南方医院 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用
CN113684277B (zh) * 2021-09-06 2022-05-17 南方医科大学南方医院 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用

Also Published As

Publication number Publication date
MXPA05014220A (es) 2006-03-09
AU2004256182A1 (en) 2005-01-20
BRPI0412110A (pt) 2006-11-21
WO2005005661A3 (fr) 2005-07-14
JP2007526749A (ja) 2007-09-20
EP1644522A2 (fr) 2006-04-12
CA2531091A1 (fr) 2005-01-20
WO2005005661A2 (fr) 2005-01-20

Similar Documents

Publication Publication Date Title
US20070198198A1 (en) Methods and apparatuses for diagnosing AML and MDS
EP2504451B1 (fr) Procédés destinés à prédire l'issue clinique d'un cancer
US20030224411A1 (en) Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US20090203588A1 (en) Outcome prediction and risk classification in childhood leukemia
US20040018513A1 (en) Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling
US20110230372A1 (en) Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia
US20050095607A1 (en) Breast cancer signatures
WO2003039443A2 (fr) Nouveaux marqueurs genetiques pour leucemies
US20060240441A1 (en) Gene expression profiles and methods of use
US20120277999A1 (en) Methods, kits and arrays for screening for, predicting and identifying donors for hematopoietic cell transplantation, and predicting risk of hematopoietic cell transplant (hct) to induce graft vs. host disease (gvhd)
KR20100095564A (ko) 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
CN1845999A (zh) 在卵巢癌中作为预后和治疗靶标而被调控的基因
KR20140006898A (ko) 결장암 유전자 발현 시그니처 및 이용 방법
CN1890381A (zh) 诊断乳腺癌的方法
US20090118132A1 (en) Classification of Acute Myeloid Leukemia
KR20090078365A (ko) 혈액 백혈구 마이크로어레이 분석을 통한 전이성 흑색종의 진단 및 면역억제 지표의 모니터링
CN101180407A (zh) 白血病疾病基因和其用途
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
US10106855B2 (en) Genetic assay to determine prognosis in Polycythemia Vera patients
EP1592811A2 (fr) Procedes pour controler in vivo des activites de medicaments
US20050164196A1 (en) Methods to predict patient responsiveness to tyrosine kinase inhibitors
US20070134690A1 (en) Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis
CN1908189A (zh) 体外辅助鉴定肠型胃癌及其分化程度的方法与专用试剂盒
EP2373816A2 (fr) Procédés de dépistage, prédiction et surveillance du cancer de la prostate
US20030175761A1 (en) Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication